Tabelecleucel, sold under the brand name Ebvallo, is a medication used for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
[2][3] Tabelecleucel is an allogeneic, EBV-specific T-cell immunotherapy which targets and eliminates EBV-infected cells in a human leukocyte antigen (HLA)-restricted manner.
[2] It is made of cells of the immune system called T-cells that have been taken from the recipient (allogeneic) and are then mixed with EBV-infected B-cells from the same donor.
First-line treatments of PTLD include monoclonal antibodies such as rituximab and chemotherapy if cancer has developed.
[3] The EMA recommendation is based on the results of an ongoing multicenter, phase III, single-arm, open-label clinical trial.